



Sanofi Innovation Awards (iAwards)

2021 Sanofi iAwards: Call-for-Proposals

Sanofi iAwards program is a multi-institutional academic partnership program designed to collaborate with academic investigators to quickly move promising early stage, disease relevant, innovative research towards the clinic. **Through this program, Sanofi aims to fund innovative and translational research ideas that can contribute to our early stage pipeline and ultimately benefit patients.**

Each selected proposal will receive:

- **\$125,000 research funding (including institutional indirect costs) for 12 months**
- **Sanofi scientific expertise and guidance**
- **In-kind resources such as reagents, tool compounds, etc. may be provided**
- **Successful projects could be converted to SRAs and receive additional funding for 2-3 years**

Sanofi iAwards General Timeline

Action	Due Date
Submission of non-confidential summary by Institution	May 31, 2021
Invitation of pre-proposal submission	June 23, 2021
Submission of pre-proposal by Institution	June 30, 2021
Notification by Sanofi of pre-proposals chosen to be pursued as Full Proposals	July 9, 2021
Completion and submission of Full Proposals	July 30, 2021
JSSC meets to review Full Proposals	September 2021*
Institution informed of JSSC funding decisions	October 2021*

* subject to change

Confidential- please do not distribute outside of your institution



Sanofi Innovation Awards (*iAwards*)

Areas of Interest

Sanofi is seeking the following type of opportunities in the therapeutics areas provided below:

- New and actionable knowledge about disease relevant targets, pathways and mechanisms
- Early stage compounds or biologics targeting novel disease mechanisms
- New models for validating disease relevant targets
- Technology platforms with the potential to significantly improve drug discovery and development (examples – gene therapy, biologics development)
- Novel therapeutic modalities

IMMUNOLOGY & INFLAMMATION

- Diseases associated with dysregulated Type 2 immune responses including Atopic Dermatitis and Asthma
- Rheumatological disorders including Lupus Erythematosus, Rheumatoid Arthritis, psoriatic arthritis, and Ankylosing spondylitis
- Autoimmune sequelae of checkpoint inhibition
- Co-stimulation pathways in autoimmune and allergic diseases
- Systems Immunology and single (immune) cell analysis
- Immuno-metabolism

RARE DISEASES

- Novel targets, models and therapeutic concepts for rare muscular dystrophies, kidney, metabolic, bleeding, and lysosomal storage diseases
- Immunogenicity of FVIII and mechanisms of tolerance induction
- Structural understanding of blood coagulation factors complexes on phospholipid surfaces
- Role complement cascade in the pathophysiology of rare and common disorders, including kidney, blood, eye, and CNS diseases

NEUROLOGICAL DISORDERS

- Novel targets, assays, models and therapeutic concepts for proteinopathies, in particular for synucleinopathies, tauopathies and TDP-43 driven diseases
- Novel targets and mechanisms to achieve neuroprotection in neurodegenerative diseases including MS, PD and ALS/FTD
- Novel approaches to address nucleotide repeat expansion diseases, including small molecules
- Novel targets, models and therapeutic concepts for neuromuscular diseases
- Novel targets and therapeutic concepts, including gene therapy, for rare genetic diseases of the central nervous system, peripheral nervous system and the kidney
- Biology, transport mechanisms and delivery across the blood brain barrier
- Biomarkers and imaging methodologies to facilitate disease diagnosis, evaluation of disease progression and therapeutic

efficacy, or patient stratification, for MS, PD and other neurodegenerative diseases

GENOMIC MEDICINE

- Gene therapy applied primarily to rare diseases, rare blood disorders, CNS, musculoskeletal diseases and the kidney
- In vivo gene delivery in liver, brain, muscle and eye
- CNS gene delivery and/or neuromuscular gene delivery technologies such as AAV capsids that enable recombinant virus penetration of blood-brain barrier following intravenous, intracerebroventricular or intrathecal delivery approaches
- AAV platform and other gene delivery technology (non-AAV platform), such as virus-free gene delivery
- Triple transfection technology (TTX) as complementary/alternative approach to a robust AAV production method
- Technologies that improve CMC processes and productivity

IMMUNO-ONCOLOGY

- Allogenic NK cell therapy in solid tumors
- *in situ* generation of CAR T or CAR NK via delivery of targeted lipid nanoparticle carrying mRNA (or other methods)
- Mechanisms of innate and acquired resistance to checkpoint blockade
- Immuno-modulatory function of TGF- β
- Immune cell engagers (NK cells & T cells engagers)
- Immuno-conjugates
- Intra-tumoral Treg depletion, modulation of immunosuppressive myeloid lineages
- Immune profiling methodologies in preclinical and clinical setting
- Novel translational models in immuno-oncology

MOLECULAR ONCOLOGY

Sanofi priority indications are breast, lung, multiple myeloma, prostate but also could be other cancers pending on target or modality.

- Novel targets and/or early drug discovery projects in molecularly-defined cancer populations and/or lineage
- Tumor induced immune suppression: regulation of anti-tumor immunity when the target is in tumor cells
- Tumors microenvironment targeting programs
- Modality: targeted protein degradation (PROTAC, Glue, monovalent degrader)

BIOLOGICS RESEARCH

- Specific tissue delivery of biologics
- In silico design / Computational biologics
- Intracellular biologics
- Multi specific protein formats